Pulmonary arterial hypertension. Part II: Medical and surgical treatment;L'ipertensione arteriosa polmonare. Parte II: Terapia medica e chirurgica

Giornale Italiano di Cardiologia

Volumn 10, Issue 6, 2009, Pages 366-381

  Manes, Alessandra ^a   Marinelli, Alessandro ^a   Palazzini, Massimiliano ^a   Negro, Luca ^a   Leci, Enri ^a   Gambetti, Simona ^a   Bachetti, Cristina ^a   Beciani, Elena ^a   Conficoni, Elisa ^a   Branzi, Angelo ^a   Galiè, Nazzareno ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Endothelin receptor antagonists; Medical surgery; Phosphodiesterase inhibitors; Prostanoids; Pulmonary hypertension; Surgery

Indexed keywords

ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; ILOPROST; PLACEBO; PROSTACYCLIN; SILDENAFIL; TADALAFIL; UNIPROST;

ABDOMINAL CRAMP; ALGORITHM; ANTICOAGULANT THERAPY; BALLOON DILATATION; BIRTH CONTROL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE CLASSIFICATION; DRUG MEGADOSE; FLUSHING; HEART LUNG TRANSPLANTATION; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG BLOOD VESSEL; LUNG TRANSPLANTATION; MONOTHERAPY; NAUSEA; OXYGEN THERAPY; PHYSICAL ACTIVITY; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VASODILATATION;

ALGORITHMS; ANGIOPLASTY, BALLOON; ANTICOAGULANTS; CALCIUM CHANNEL BLOCKERS; CARDIOTONIC AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; DIGOXIN; DIURETICS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HEART-LUNG TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; OXYGEN; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ENDOTHELIN; TREATMENT OUTCOME;

EID: 67649218372     PISSN: 18276806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114: 1482-1489 (Pubitemid 44527003)
2. Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761-781
3. Deanfield J, Thaulow E, Warnes C, et al, for the Tak Force on the management of grown up congenital disease, European Society of cardiology and the ESC Committee for Practice Guidelines. Management of grown up congenital heart disease. Eur Heart J 2003; 24: 1035-1084
4. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-587 (Pubitemid 14020655)
5. Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-1206
6. Moser KM, Fedullo PF, Finkbeiner WE, Golden J. Do patients with primary pulmonary hypertension develop extensive central thrombi? Circulation 1995; 91: 741-745
7. Hervé P, Humbert M, Sitbon O, et al. Pathobiology of pulmonary hypertension. The role of platelets and thrombosis. Clin Chest Med 2001; 22: 451-458
8. Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients with severe primary pulmonary hypertension. Eur Respir J 1998; 12: 1446-1449 (Pubitemid 29011445)
9. Huber K, Beckmann R, Frank H, Kneussl M, Mlczoch J, Binder RR. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension. Am J Respir Crit Care Med 1994; 150: 929-933 (Pubitemid 24318015)
10. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
11. Frank H, Mlczoch J, Huber K, Schuster E, Gurtner HP, Kneussl M. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. Chest 1997; 112: 714-721 (Pubitemid 27410708)
12. Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164: 1682-1687 (Pubitemid 33124159)
13. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-792 (Pubitemid 28433741)
14. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agents for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-270 (Pubitemid 28389516)
15. Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? [abstract] Am J Resp Crit Care Med 2003; 167: A440.
16. Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-3111 (Pubitemid 40847788)
17. Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278 Le linee guida riassumono in maniera analitica e semplice gli aspetti patobiologici, fisiopatologici e clinici dell'ipertensione arteriosa polmonare.
18. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76: 135-141 (Pubitemid 17093201)
19. Raffy O, Azarian R, Brenot F, et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996; 93: 484-488 (Pubitemid 126425249)
20. Galiè N. Do we need controlled clinical trials in pulmonary arterial hypertension? Eur Respir J 2001; 17: 1-3.
21. Nootens M, Kaufmann E, Rich S. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. Am J Cardiol 1993; 71: 1475-1476 (Pubitemid 23172711)
22. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088-1093 (Pubitemid 37323574)
23. Jones DA, Benjamin CW, Linseman DA. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. Mol Pharmacol 1995; 48: 890-896
24. Galiè N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2003; 2: 123-137 Questa rassegna descrive le caratteristiche farmacocinetiche e farmacodinamiche e il razionale d'uso dei diversi prostanoidi (farmaci analoghi della prostaciclina) disponibili per il trattamento dell'ipertensione arteriosa polmonare, nonché gli studi clinici controllati che ne hanno documentato l'efficacia. (Pubitemid 37062722)
25. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-491 (Pubitemid 20100285)
26. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
27. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-434 (Pubitemid 30149039)
28. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788 (Pubitemid 34925627)
29. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-1482 (Pubitemid 35050873)
30. McLaughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130: 740-743 (Pubitemid 29211512)
31. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-1865 (Pubitemid 29181415)
32. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin). A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30: 641-648
33. Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-1439 (Pubitemid 36609730)
34. Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007; 26: 357-362 (Pubitemid 46522504)
35. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208 (Pubitemid 29120092)
36. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34: 1184-1187 (Pubitemid 29500558)
37. Olschewski H, Simonneau G, Galiè N, et al, for the Aerosolized Iloprost Randomized Study Group. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329
38. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006; 174: 1257-1263 (Pubitemid 44924827)
39. Opitz CF, Wensel R, Winkler J, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005; 26: 1895-1902 (Pubitemid 41253303)
40. Higenbottam T, Butt AY, McMahon A, Westerbeck R, Sharples L. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80: 151-155 (Pubitemid 28389476)
41. Simonneau G, Barst RJ, Galiè N, et al, for the Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804 (Pubitemid 34229650)
42. Barst RJ, Galiè N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28: 1195-1203. (Pubitemid 44883856)
43. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006; 129: 1636-1643 (Pubitemid 43894997)
44. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 2004; 44: 209-214 (Pubitemid 38982164)
45. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129: 683-688
46. Sitbon O, Manes A, Jais X, et al. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension. J Cardiovasc Pharmacol 2007; 49: 1-5. (Pubitemid 46184324)
47. Galiè N, Humbert M, Vachiéry JL, et al, for the Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomised, double-blind placebo-controlled trial. J Am Coll Cardiol 2002; 39: 1496-1502
48. Barst RJ, McGoon M, McLaughlin VV, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125 (Pubitemid 36724255)
49. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61: 227-237 Questa rassegna descrive le caratteristiche dell'endotelina-1, un polipeptide prodotto principalmente dalle cellule endoteliali con potente effetto vasocostrittore, pro-mitogeno e profibrotico. (Pubitemid 38091763)
50. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991; 114: 464-469
51. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739 (Pubitemid 23170122)
52. Clozel M, Breu V, Gray GA, Löffler BM. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. J Cardiovasc Pharmacol 1993; 22 (Suppl 8): S377-S379.
53. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123 (Pubitemid 32971843)
54. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903. (Pubitemid 34984638)
55. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-359 (Pubitemid 39232254)
56. Galiè N, Beghetti M, Gatzoulis MA, et al, for the Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48-54.
57. Galiè N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100 (Pubitemid 351902178)
58. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-249 (Pubitemid 40246523)
59. Barst RJ, Langleben D, Frost A, et al, for the STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447
60. Barst R, Langleben D, Badesch BD, et al, for the STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056
61. Benza RL, Barst RJ, Galiè N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134: 775-782
62. Galiè N, Badesch BD, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-535 (Pubitemid 41040298)
63. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in pulmonary arterial hypertension, Randomized, double-blind, placebo-controlled, multicenter. Efficacy (ARIES) Study 1 and 2. Circulation 2008; 117: 3010-3019
64. Wharton J, Strange JW, Møller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005; 172: 105-113 (Pubitemid 40923321)
65. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004; 44: 1488-1496 (Pubitemid 39303954)
66. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343: 1342. (Pubitemid 30808135)
67. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003; 108: 2066-2069 (Pubitemid 37337580)
68. Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167: 1139-1141 (Pubitemid 36459662)
69. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30: 922-927 (Pubitemid 351194796)
70. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900. (Pubitemid 35283832)
71. Oudiz RJ, Roveran G, Hansen JE, Sun XG, Wasserman K. Effect of sildenafil on ventilatory efficiency and exercise tolerance in pulmonary hypertension. Eur J Heart Fail 2007; 9: 917-921 (Pubitemid 47332322)
72. Singh TP, Rohit M, Grover A, Malhotra S, Vijayvergiya R. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006; 151: 851.e1-e5.
73. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149-1153 (Pubitemid 38452588)
74. Galiè N, Ghofrani HA, Torbicki A, et al, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157
75. Badesch DB, Hill NS, Burgess G, et al, for the SUPER Study Group. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007; 34: 2417-2422
76. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005; 60: 107-112 (Pubitemid 40942789)
77. Galiè N, Brundage B, Ghofrani A, et al. Tadalafil therapy in pulmonary arterial hypertension: results of a randomized, double-blind, placebo-controlled, phase III study [abstract]. Eur Heart J 2008; 29 (Suppl): 519.
78. Wrishko RE, Dingemanse J, Yu A, Darstein C, Phillips DL, Mitchell MI. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. J Clin Pharmacol 2008; 48: 610-618
79. Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164 (Pubitemid 36760778)
80. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004; 24: 1007-1010
81. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 330-334 (Pubitemid 36987006)
82. Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29: 469-475 (Pubitemid 46372092)
83. Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863
84. Hoeper M, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28: 691-694 (Pubitemid 46331988)
85. Simonneau G, Rubin L, Galiè N, et al, for the PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Intern Med 2008; 149: 521-530
86. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15: 100-105 (Pubitemid 26056129)
87. Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J 1986; 55: 449-458 (Pubitemid 16122489)
88. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304. (Pubitemid 28396475)
89. Reichenberger F, Pepke-Zaba J, McNeil K, Parameshwar J, Shapiro LM. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58: 797-800. (Pubitemid 37094058)
90. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007; 131: 977-983 (Pubitemid 46608695)
91. Ciarka A, Vachiéry JL, Houssière A, et al. Atrial septostomy decreases sympathetic overactivity in pulmonary arterial hypertension. Chest 2007; 131: 1831-1837 (Pubitemid 46981642)
92. Naeije R, Vachiéry JL. Medical therapy of pulmonary hypertension. Conventional therapies. Clin Chest Med 2001; 22: 517-527
93. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-755
94. Boujoukos AJ, Martich GD, Vega JD, Keenan RJ, Griffith BP. Reperfusion injury in single lung transplant recipients with pulmonary hypertension and emphysema. J Heart Lung Transplant 1997; 16: 439-448 (Pubitemid 27199601)
95. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant 2002; 21: 731-737 (Pubitemid 34718178)
96. Trulock EP, Edwards LB, Taylor DO, Boocek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report - 2006. J Heart Lung Transplant 2006; 25: 880-892 (Pubitemid 44143015)